NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

NCT04609319

CompletedN/A

Sponsor: Pfizer

Conditions: Lung Cancer

Interventions: Dacomitinib

Countries: China, India, Malaysia

This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) treated with dacomitinib as first-line therapy from the date of advanced NSCLC diagnosis to the date of death, lost to follow-up, withdrawal of consent or end of study, whichever occurs first.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult (aged ≥18 years) with histology-confirmed advanced NSCLC (TNM stage IIIB-IV);
* Presence of any EGFR-activating mutation (exon 19 deletion or exon 21 L858R substitution) or other uncommon EGFR mutations prior to anti-cancer treatment;
* Initiating dacomitinib as first-line treatment after confirmation of EGFR-mutation status (ie, no prior treatment with other EGFR TKI or systemic therapy);

Exclusion Criteria:

* Enrolled in any interventional clinical study or trial (however, patients enrolled in non-interventional, real world study may still be included).

Locations (14)

Beijing, Beijing Municipality, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Zhengzhou, Henan, China
Changsha, Hunan, China
Changchun, Jilin, China
Chengdu, Sichuan, China
Beijing, China
Shenyang, Liaoning Province, China
New Delhi, DEL, India
Kolkata, West Bengal, India
Kuala Lumpur, Malaysia
Kuala Lumpur, Malaysia
Petaling Jaya, Malaysia